Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
PaperCitations, authors & open-access status
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 674 citations, 2013 year and hybrid oa status.
674
Citations
2013
Year
hybrid
OA Status